

Supplementary material

Pawlicka A, Wężyk K, Matwiej K, et al. Safety of COVID-19 vaccines and factors influencing the vaccine take-up rate in Polish adults with epilepsy: a single-center study. *Pol Arch Intern Med.* 2023; 133: 16389. doi:10.20452/pamw.16389

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Figure S1. The frequency and types of adverse events after the first and second dose.




Table S1. Comparison of demographics, epilepsy characteristics, disability, and comorbidities between patients with and without vaccine-related adverse events.

Variables	Adverse events- yes n= 130 (%)	Adverse events - no n= 37 (%)	<i>P</i> value ¹
Gender (n, %) Females	80 (61.5)	15 (40.5)	<i>P</i> = 0.03
Median age, (Q1-Q3)	36.0 (29.0-43.0)	35.0 (25.0-40.0)	<i>P</i> = 0.12
Median age at onset of epilepsy, (Q1-Q3)	16.0 (8.0-23.0)	14.0 (8.0-20.0)	<i>P</i> = 0.63

Epilepsy type			<i>P</i> = 0.13
Generalized	36 (27.7)	5 (13.5)	
Focal	87 (66.9)	30 (81.1)	
Combined	3 (2.3)	2 (5.4)	
Unknown	4 (3.1)	0	
seizure freedom yes	45 (34.6)	12 (32.4)	<i>P</i> = 0.85
polytherapy yes	63 (48.5)	17 (45.9)	<i>P</i> = 0.85
intellectual disability yes	22 (16.9)	11 (29.7)	<i>P</i> = 0.10
physical disability yes	17 (13.1)	11 (29.7)	<i>P</i> = 0.02
comorbidities yes	51 (39.2)	16 (43.2)	<i>P</i> = 0.70

1 χ^2 test (or Fisher exact test where appropriate) except for age (Mann-Whitney U-test)